LIPELLA PHARMACEUTICALS INC. (LIPO): Nasdaq/NYSE listing notice — Lipella receives Nasdaq deficiency notice for potential minimum equity violation

LIPELLA PHARMACEUTICALS INC.

Received Nasdaq notice on Nov 21, 2023, for failure to maintain minimum $2.5M stockholders' equity as of Sep 30, 2023.
No immediate effect on listing of LIPO common stock; continues to trade normally.
Company evaluating measures to regain compliance but cannot assure success.
If not remedied, Nasdaq may delist the stock; compliance deadline not specified.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

LIPELLA PHARMACEUTICALS INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 21, 2023, Lipella Pharmaceuticals Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company may have failed to maintain a required minimum of $2,500,000 in stockholders’ equity for continued listing, as required under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”), based on the financial results reported in the Company’s Form 10-Q for the period ended September 30, 2023, as filed with the SEC on November 14, 2023. The Notice has no immediate effect on the listing of the Company’s common stock, par value $0.0001 per sha

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-23-001555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.